Abstract
Defensins and cathelicidins are small cationic peptides produced by neutrophils and epithelial cells. They are highly expressed during infection. The role of constitutive and inducible antibacterial peptides has been extensively studied over the recent years; especially in the gastrointestinal (GI) tract, where the balance between the luminal bacteria and antibacterial peptides is crucial in the maintenance of a healthy GI tract. There are reports showing that the expressions of defensins and cathelicidins in the gut are dysregulated in various disease states. They could participate in the development of different disorders ranging from inflammation to cancer. Experimental findings showed that supplementation with animal cathelicidin promoted gastric ulcer healing in rats and suppressed tumorigenesis of gastric cancer in mice. Mouse cathelicidin could alleviate murine colitis by preserving mucus content and suppression of apoptosis. Other clinical applications for these antibacterial peptides are awaiting for further studies.
Keywords: Defensins, Cathelicidins, Gastritis, Gastric cancer, Inflammatory bowel diseases, neutrophils, peptides, tumorigenesis, metaplasia, magainins, ceropins, in situ, hybridization, hBD-2, hBD-3, hyperexpression, peptidoglycan
Current Pharmaceutical Design
Title: Antibacterial Peptides and Gastrointestinal Diseases
Volume: 17 Issue: 16
Author(s): Clover C. M. Wong, Lin Zhang, Shun X. Ren, Jing Shen, Ruby L. Y. Chan and Chi H. Cho
Affiliation:
Keywords: Defensins, Cathelicidins, Gastritis, Gastric cancer, Inflammatory bowel diseases, neutrophils, peptides, tumorigenesis, metaplasia, magainins, ceropins, in situ, hybridization, hBD-2, hBD-3, hyperexpression, peptidoglycan
Abstract: Defensins and cathelicidins are small cationic peptides produced by neutrophils and epithelial cells. They are highly expressed during infection. The role of constitutive and inducible antibacterial peptides has been extensively studied over the recent years; especially in the gastrointestinal (GI) tract, where the balance between the luminal bacteria and antibacterial peptides is crucial in the maintenance of a healthy GI tract. There are reports showing that the expressions of defensins and cathelicidins in the gut are dysregulated in various disease states. They could participate in the development of different disorders ranging from inflammation to cancer. Experimental findings showed that supplementation with animal cathelicidin promoted gastric ulcer healing in rats and suppressed tumorigenesis of gastric cancer in mice. Mouse cathelicidin could alleviate murine colitis by preserving mucus content and suppression of apoptosis. Other clinical applications for these antibacterial peptides are awaiting for further studies.
Export Options
About this article
Cite this article as:
C. M. Wong Clover, Zhang Lin, X. Ren Shun, Shen Jing, L. Y. Chan Ruby and H. Cho Chi, Antibacterial Peptides and Gastrointestinal Diseases, Current Pharmaceutical Design 2011; 17 (16) . https://dx.doi.org/10.2174/138161211796197025
DOI https://dx.doi.org/10.2174/138161211796197025 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Study on Nutrient and Medicinal Compositions of Selected Indian Garcinia Species
Current Bioactive Compounds Personalized Medicine in Oncology: A Personal View with Myths and Facts
Current Clinical Pharmacology Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry Formulation and Application of Biodegradable Nanoparticles Based Biopharmaceutical Delivery - An Efficient Delivery System
Current Pharmaceutical Design microRNA Decay: Refining microRNA Regulatory Activity
MicroRNA From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Thioethers: An Overview
Current Drug Targets Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Carbonic Anhydrase Related Protein VIII and its Role in Neurodegeneration and Cancer
Current Pharmaceutical Design Quercetin-Phospholipid Complex: An Amorphous Pharmaceutical System in Herbal Drug Delivery
Current Drug Discovery Technologies Discovery of New Inhibitors of Urease Enzyme: A Study Using STD-NMR Spectroscopy
Letters in Drug Design & Discovery Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Personalized Therapy In Cancer of Digestive System)
Clinical Cancer Drugs Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Genetics of Bladder Malignant Tumors in Childhood
Current Genomics The Posttranslational Phase of Gene Expression: New Possibilities in Molecular Diagnosis
Current Molecular Medicine Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry Pharmacokinetics of CNT-based Drug Delivery Systems
Current Drug Metabolism “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Development of a Multi-Compartmental Oral Vaccine Delivery System
Drug Delivery Letters